Shareholder Alert: The Ademi Firm investigates whether Amicus Therapeutics, Inc. is obtaining a Fair Price for its Public Shareholders

MILWAUKEE, Dec. 19, 2025 /PRNewswire/ -- The Ademi Firm is investigating Amicus (Nasdaq: FOLD) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with BioMarin.

Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995.  There is no cost or obligation to you.

In the transaction, Amicus shareholders will receive $14.50 per share in an all-cash transaction valued at approximately $4.8 billion. Amicus insiders will receive substantial benefits as part of change of control arrangements.

The transaction agreement unreasonably limits competing transactions for Amicus by imposing a significant penalty if Amicus accepts a competing bid. We are investigating the conduct of the Amicus board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Ademi & Fruchter LLP                                 
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001

View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-the-ademi-firm-investigates-whether-amicus-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders-302646931.html

SOURCE Ademi LLP